Actinium Pharmaceuticals presents results of Phase 3 SIERRA trial of Iomab-B

Actinium Pharmaceuticals announced that results from the Phase 3 SIERRA trial of Iomab-B were presented at the 2024 European Hematology Association Hybrid Congress being held June 13 – 16, 2024, in Madrid, Spain. The two presentations at EHA highlighted outcomes in patients with active relapsed or refractory acute myeloid leukemia enrolled in the SIERRA trial who had a TP53 mutation and long-term efficacy results in this older patient population. The Phase 3 SIERRA trial enrolled 153 patients ages 55 and above with active r/r AML and compared outcomes of patients receiving an Iomab-B led bone marrow transplant to those of patients receiving physician’s choice of care in the control arm. Across all patients in SIERRA study, only patients receiving an Iomab-B led BMT achieved the trial’s primary endpoint of durable complete remission with these patients having 92% 1-year survival and 69% 2-year survival with statistically significant higher event free survival. The SIERRA trial enrolled high-risk patients including those with one or more of the following: a TP53 mutation, advanced age up to 77 years old, complex cytogenetics and prior therapy including venetoclax and other targeted agents.